FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097092893> ?p ?o ?g. }

• W3097092893 endingPage "22" @default.
• W3097092893 startingPage "21" @default.
• W3097092893 abstract "Background and objectives:Gaucher disease (GD) is renowned for genotype/phenotype studies and therapeutic innovation. However, the vast majority of the literature is focused on Type 1 GD related to the founder mutation, p.Asn409Ser in GBA gene although p.Leu483Pro GBA mutation associated GD may be far more prevalent across the world. In Egypt GD represents as high as 14.7% of all reported lysosomal disorders with the neuronopathic forms. Therefore, a large single center cohort study of a highly consanguineous GD population has the potential to inform genotype/phenotype, natural history studies and illuminate unmet needs. Methods:At University of Cairo's Pediatric Hematology Clinic since 1998, we have managed a total of 156 patients with GD with longitudinal data captured under an approved IRB protocol. In the present study, we focused analysis on 85 patients in whom we had long-term outcome after 20 years of enzyme replacement therapy (ERT). GBA gene analysis was performed by whole exome sequencing of DNA isolated from dry blood spots. Data on the clinical phenotype indicators at baseline and during ERT were collected including liver and spleen volumes, growth parameters, bone status, neurological assessment and eye movement. SPSS (Statistical Package for the Social Sciences) version 24 was used to compile data, assess significance and survival by Kaplan Meier analysis. Overall survival (OS) is defined as date of diagnosis till date of death, patients alive or lost during follow up was considered censored till the last date of follow up. Results:The median age at diagnosis was 1 year (IQR: 0.08-15 years) with majority (64.7%) diagnosed in first 2 years of life (range 0.5-2 yrs). The patient population was highly consanguineous and 51% of the patients reported positive family history of GD. The most prevalent genotype (75% of patients) was p.Leu483Pro homozygous. Homozygosity for p.Asp448His was present in 11% of patients. Other GBA mutations included: p.Leu483Pro homozygous in 3 patients, one heteroallelic with p.Leu483Pro; pArg87Trp homozygous in 2 patients; p.Arg398Gln homozygous in one patient). Hematological features of patients at diagnosis revealed anemia in 76% and thrombocytopenia in 22%. Massive splenomegaly (˃15 Multiples of Normal by ultrasonography) was present in 49%, 4 patients were splenectomised, hepatomegaly (˃2.5 MN) in 11%, liver cirrhosis with hepatopulmonary syndrome in one patient. Skeletal findings included multiple fractures in 3 patients and kyphosis in 3 patients. The most common neurological findings were oculomotor apraxia, squint and bulbar symptoms (48%, 30.6% and 29.4% respectively). Bone marrow examination showed Gaucher cell infiltration in 76% of the patients. Patients received Imiglucerase (Cerezyme) dose individualized by baseline disease severity. Debilitating and potentially life-threatening visceral and hematologic disease was reversed with ERT (table 1). One splenectomized patient with massive hepatomegaly and hepatopulmonary syndrome showed complete reversal on high dose ERT. Preliminary observer reported outcomes (by clinician and parent) with respect to neurological findings including oculomotor apraxia appeared to show mild improvement. Follow-up of 10 patients in whom ERT was initiated early had striking overall outcomes progressing through school and university. At 20 years, the overall survival was 71%; 20 patients died from disease complications mostly pulmonary and progressive neurological disease. Comparison of the OS in relation to gender, age at diagnosis, severity of hematological and visceral parameters showed that none of the studied variables affects OS (p˃0.05) (fig. 1). Conclusion:This study represents the largest and most extensive single-center cohort of GD3 patients with predominant p.Leu483Pro homozygous GBA genotype, without presence of a complex allele. Patients had uniformly very early-onset disease before age 2 years with devastating hematological and visceral disease which was effectively reversed by ERT. During 20 year-follow up of the cohort, there was striking reversal of hematovisceral disease and about a third of the patients succumbed to complications of GD3. OS was not correlated with severity of baseline disease underscoring the potential role of modifier genes. Disclosures No relevant conflicts of interest to declare." @default.
• W3097092893 created "2020-11-09" @default.
• W3097092893 creator A5006550170 @default.
• W3097092893 creator A5018337536 @default.
• W3097092893 creator A5023178982 @default.
• W3097092893 creator A5029650400 @default.
• W3097092893 creator A5055529584 @default.
• W3097092893 creator A5069567664 @default.
• W3097092893 creator A5069576915 @default.
• W3097092893 creator A5071386625 @default.
• W3097092893 date "2020-11-05" @default.
• W3097092893 modified "2023-09-30" @default.
• W3097092893 title "Largest Cohort Study of Gaucher Disease Type 3 from a Single Center in Egypt Spanning Two Decades" @default.
• W3097092893 doi "https://doi.org/10.1182/blood-2020-141776" @default.
• W3097092893 hasPublicationYear "2020" @default.
• W3097092893 type Work @default.
• W3097092893 sameAs 3097092893 @default.
• W3097092893 citedByCount "0" @default.
• W3097092893 crossrefType "journal-article" @default.
• W3097092893 hasAuthorship W3097092893A5006550170 @default.
• W3097092893 hasAuthorship W3097092893A5018337536 @default.
• W3097092893 hasAuthorship W3097092893A5023178982 @default.
• W3097092893 hasAuthorship W3097092893A5029650400 @default.
• W3097092893 hasAuthorship W3097092893A5055529584 @default.
• W3097092893 hasAuthorship W3097092893A5069567664 @default.
• W3097092893 hasAuthorship W3097092893A5069576915 @default.
• W3097092893 hasAuthorship W3097092893A5071386625 @default.
• W3097092893 hasConcept C104317684 @default.
• W3097092893 hasConcept C126322002 @default.
• W3097092893 hasConcept C16671776 @default.
• W3097092893 hasConcept C187212893 @default.
• W3097092893 hasConcept C2779134260 @default.
• W3097092893 hasConcept C2908647359 @default.
• W3097092893 hasConcept C501734568 @default.
• W3097092893 hasConcept C54355233 @default.
• W3097092893 hasConcept C71924100 @default.
• W3097092893 hasConcept C72563966 @default.
• W3097092893 hasConcept C86803240 @default.
• W3097092893 hasConcept C99454951 @default.
• W3097092893 hasConceptScore W3097092893C104317684 @default.
• W3097092893 hasConceptScore W3097092893C126322002 @default.
• W3097092893 hasConceptScore W3097092893C16671776 @default.
• W3097092893 hasConceptScore W3097092893C187212893 @default.
• W3097092893 hasConceptScore W3097092893C2779134260 @default.
• W3097092893 hasConceptScore W3097092893C2908647359 @default.
• W3097092893 hasConceptScore W3097092893C501734568 @default.
• W3097092893 hasConceptScore W3097092893C54355233 @default.
• W3097092893 hasConceptScore W3097092893C71924100 @default.
• W3097092893 hasConceptScore W3097092893C72563966 @default.
• W3097092893 hasConceptScore W3097092893C86803240 @default.
• W3097092893 hasConceptScore W3097092893C99454951 @default.
• W3097092893 hasIssue "Supplement 1" @default.
• W3097092893 hasLocation W30970928931 @default.
• W3097092893 hasOpenAccess W3097092893 @default.
• W3097092893 hasPrimaryLocation W30970928931 @default.
• W3097092893 hasRelatedWork W2071535500 @default.
• W3097092893 hasRelatedWork W2082482010 @default.
• W3097092893 hasRelatedWork W2315085516 @default.
• W3097092893 hasRelatedWork W2316407790 @default.
• W3097092893 hasRelatedWork W2603773853 @default.
• W3097092893 hasRelatedWork W2765379856 @default.
• W3097092893 hasRelatedWork W2952239533 @default.
• W3097092893 hasRelatedWork W2964295425 @default.
• W3097092893 hasRelatedWork W2999832097 @default.
• W3097092893 hasRelatedWork W3191836161 @default.
• W3097092893 hasVolume "136" @default.
• W3097092893 isParatext "false" @default.
• W3097092893 isRetracted "false" @default.
• W3097092893 magId "3097092893" @default.
• W3097092893 workType "article" @default.